Mankind Pharma is focusing on women's health and fertility to meet the increasing demand for specialized healthcare products. The company has acquired Bharat Serums and Vaccines (BSV) for Rs 13,630 crores, strengthening its position in the Indian women's health segment. The acquisition will enhance Mankind Pharma's offerings, covering the entire lifecycle from fertility to post-pregnancy.
Rajeev Juneja, Vice-Chairman and Managing Director, of Mankind Pharma Ltd. mentioned, "BSV's acquisition will support our position in the Indian women's health and fertility segment. We see significant opportunities in this sector with positive growth prospects globally." BSV provides Women's Health, Fertility, and Critical Care products, aligning with Mankind Pharma's strategy and expanding into Indian and international fertility markets.
Mankind Pharma is a leading pregnancy kit manufacturer that offers products like Unwanted-72, Nufol, Dydroboon, Dutan, Clear Gel, Unwanted Kit, and Fertisure-F AND Fertisure-M, contributing to its strong presence in India's women's health and fertility market.
The Indian women's healthcare market is expected to grow significantly, with a projected CAGR of 11.5 per cent from 2024 to 2030. The market is valued at Rs 31,000 crores in 2023 and is projected to reach Rs 3,40,000 crores by 2028. The fertility sector is also expected to grow to Rs 2,71,000 crores by 2027 at a CAGR of 10.2 per cent from 2022.
